ClinicalTrials.gg
CompletedNCT04814186Updated Dec 18, 2024Results posted

A Study to Assess the Safety and Efficacy Of Tafamidis In Chinese Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

A Phase 4 interventional study of Tafamidis in Transthyretin Amyloid Cardiomyopathy, sponsored by Pfizer. Completed at 9 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-18.

Sponsored by Pfizer · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
53
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a national, multi-center, single-arm study, open-label to patients with symptomatic Transthyretin amyloid cardiomyopathy (ATTR-CM) who are tafamidis naïve. This study is to obtain safety, descriptive efficacy, Pharmacokinetics (PK) and Pharmacodynamics (PD) data for tafamidis orally once daily.

Subject eligibility for participation in the study will receive tafamidis once daily or 12 months following the assessment as the screening and baseline, month 1, 3, 6, 9 and 12 visits (or Early Study Discontinuation).

02

Conditions studied

  • Transthyretin Amyloid Cardiomyopathy

Keywords

  • Tafamidis
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject has documented ATTR-CM.
  2. For the reproductive criteria for male and female participants, please refer to relevant protocol sections.

Exclusion criteria

Exclusion Criteria:

  1. Other acute or chronic medical or psychiatric condition including recent or active suicidal ideation or behavior or laboratory abnormality, in the judgment of the investigator, would make the participant inappropriate for entry into this study.
  2. Participants who have prior liver and/or heart transplant.
  3. Participants with primary (light chain) or secondary amyloidosis.
  4. Previous administration with an drug within 30 days or 5 half lives preceding the first dose of study intervention used in this study (whichever is longer).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
53 participants (actual)

Study arms

  • Experimental
    Chinese participants treated with Tafamidis

    treatment group with tafamidis

    Drug: Tafamidis

Interventions

  • 61 mg, once daily, oral administration, for 12 months.

    Also known as: Vyndamax, Tafamidis free acid, PF 06291826

06

What researchers measure

Primary outcomes

  1. Number of Participants With All-Causality Treatment-Emergent Adverse Events (TEAEs)

    An adverse event (AE) was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. All AEs that started after the first dosing but before the last dose plus the lag time (28 days) were TEAEs. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience; persistent disability/incapacity; congenital anomaly/birth defect. A severe TEAE was an event that prevented normal everyday activities. Severe TEAEs were assessed by the investigator.

    Time frame: From first dose of study intervention on Day 1 (baseline) up to 28 days post the last dose of study intervention (up to a maximum of 393 days)

  2. Number of Participants With Treatment-Related TEAEs

    An AE was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. All AEs that started after the first dosing but before the last dose plus the lag time (28 days) were TEAEs. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience; persistent disability/incapacity; congenital anomaly/birth defect. A severe TEAE was an event that prevented normal everyday activities. Severe TEAEs and treatment-related TEAEs were assessed by the investigator.

    Time frame: From first dose of study intervention on Day 1 (baseline) up to 28 days post the last dose of study intervention (up to a maximum of 393 days)

Secondary outcomes

  1. Change From Baseline (CFB) for Distance Walked During 6 Minute Walk Test (6MWT) at Months 6 and 12

    As a measure of functional capacity, the 6MWT measured the distance a participant could walk on a straight course in 6 minutes. 6MWT was conducted in accordance with guidelines established by the American Thoracic Society at Month 6 and Month 12 visits. Baseline was defined as the last measurement prior to first dose of study intervention.

    Time frame: Baseline, months 6 and 12

  2. Change From Baseline for N Terminal Prohormone B Type Natriuretic Peptide (NT-proBNP) at Months 6 and 12

    Plasma NT-proBNP is a guideline-mandated biomarker in heart failure. Baseline was defined as the last measurement prior to the first dose of study treatment.

    Time frame: Baseline, months 6 and 12

  3. Percentage of Responders in Transthyretin (TTR) Stabilization Post Dose at Months 1, 6, and 12

    Blood sample of approximate 10 mL was collected at baseline, Months 1, 6, and 12 visits for measurement of TTR and TTR tetramer concentrations. TTR concentration was obtained prior to urea denaturation and TTR tetramer concentration was obtained after urea denaturation. Month 1 visit occurred 1 month post Day 1 +/- 1 week, Month 6 visit occurred 6 months post Day 1 +/- 2 weeks, and Month 12 visit occurred 12 months post Day 1 +/- 2 weeks or within 2 weeks after end of treatment. Responder was the participant who achieved TTR stabilization (ie, who had been TTR stabilized). Declaring a participant to have been (TTR) 'stabilized' was defined as the participant whose percent stabilization was equal to or greater than 32%. Percent stabilization (%) was calculated as (\[fraction of initial {FOI} dosed - FOI baseline\] / FOI baseline)×100, and FOI was calculated as average TTR tetramer concentration (post-denaturation) / average TTR concentration (pre-denaturation).

    Time frame: Predose on Day 1 (baseline), predose and 3 hours post dose at Month 1 visit, 7 hours post dose at Month 6 visit, and 1 hour post dose at Month 12 visit

  4. TTR Concentration at Baseline, Months 1, 6, and 12

    One K2EDTA blood sample of approximate 10 mL was collected on Day 1 (baseline), and at Months 1, 6, and 12 visits for measurement of TTR concentration. Month 1 visit occurred 1 month post Day 1 +/- 1 week, Month 6 visit occurred 6 months post Day 1 +/- 2 weeks, and Month 12 visit occurred 12 months post Day 1 +/- 2 weeks or within 2 weeks after end of treatment.

    Time frame: Predose on Day 1 (baseline), predose and 3 hours post dose at Month 1 visit, 7 hours post dose at Month 6 visit, and 1 hour post dose at Month 12 visit

  5. Change From Baseline for Kansas City Cardiomyopathy Questionnaire Overall Summary (KCCQ-OS) Scores at Months 6 and 12

    The KCCQ is a self-administered, 23-item questionnaire. KCCQ-OS scores are transformed to a 0 to 100 range, with lower scores denoting poorer quality of life.

    Time frame: Day 1 (baseline), Months 6, and 12

  6. Change From Baseline for EuroQol 5 Dimensions 5 Levels (EQ-5D-5L) Index Values at Months 6 and 12

    The EQ-5D-5L is a brief, self-administered generic health status instrument. The instrument consists of 2 parts. In the first part, respondents are asked to rate their current health state on 5 dimensions (mobility, self-care, usual activities, pain or discomfort, and anxiety or depression) with each dimension having 5 levels of function (no problems, slight problems, moderate problems, severe problems, and extreme problems). The second part is a participant's self-rating of current health state on a Visual Analog Scale (EQ-5D VAS) with endpoints labeled 'best imaginable health state' (score of 100) and 'worst imaginable health state' (score of 0). The index values were calculated using the scoring algorithm based on preferences solicited from the Chinese population with 0 representing death and 1 representing full health. Higher EQ-5D-5L index value indicated a better quality of life. Change from baseline for EQ-5D-5L index values are reported for this outcome measure.

    Time frame: Day 1 (baseline), Months 6, and 12

  7. Change From Baseline for EuroQol VAS at Months 6 and 12

    The EQ-5D-5L (5 levels version) is a brief, self-administered generic health status instrument. The instrument consists of 2 parts. In the first part, respondents are asked to rate their current health state on 5 dimensions (mobility, self-care, usual activities, pain or discomfort, and anxiety or depression) with each dimension having 3 levels of function (no problems, slight problems, moderate problems, severe problems and extreme problems). The second part is a participant's self-rating of current health state on a EQ-5D VAS with endpoints labeled 'best imaginable health state' (score of 100) and 'worst imaginable health state' (score of 0). The scores from the 5 dimensions may be used to calculate a single index value, also known as a utility score. EQ-5D VAS scores are reported for this outcome measure.

    Time frame: Day 1 (baseline), Months 6, and 12

  8. Change From Baseline for Physical Component Summary (PCS) for Short-Form Survey 12 (SF-12) at Months 6 and 12

    SF-12 is developed as a shorter alternative to the SF-36 for use in large-scale studies. It is an instrument with different weights for scoring physical and mental health, and measures health-related quality of life with 12 items categorized in eight areas: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. This questionnaire was completed by the participant after the KCCQ and EQ-5D-5L, and prior to other required visit assessments. PCS score ranges from 0 to 100, and higher PCS score indicates a better quality of life. Change from baseline for PCS for SF-12 is reported for this outcome measure.

    Time frame: Day 1 (baseline), Months 6, and 12

  9. Change From Baseline for Mental Component Summary (MCS) for SF-12 at Months 6 and 12

    SF-12 is developed as a shorter alternative to the SF-36 for use in large-scale studies. It is an instrument with different weights for scoring physical and mental health, and measures health-related quality of life with 12 items categorized in eight areas: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. This questionnaire was completed by the participant after the KCCQ and EQ-5D-5L, and prior to other required visit assessments. MCS score ranges from 0 to 100, and higher MCS score indicates a better quality of life. Change from baseline for MCS for SF-12 is reported for this outcome measure.

    Time frame: Day 1 (baseline), Months 6, and 12

  10. Plasma Concentrations of Tafamidis at Months 1, 6, and 12

    Blood samples of approximately 3 mL, to provide an approximately 1 mL plasma, were collected for measurement of plasma concentrations of tafamidis at Months 1, 6, and 12 visits. Month 1 visit occurred 1 month post Day 1 +/- 1 week, Month 6 visit occurred 6 months post Day 1 +/- 2 weeks, and Month 12 visit occurred 12 months post Day 1 +/- 2 weeks or within 2 weeks after end of treatment.

    Time frame: Predose and 3 hours post dose at Month 1 visit, 7 hours post dose at Month 6 visit, and 1 hour post at Month 12 visit

07

Results

Posted Dec 18, 2024

Participant flow

A total of 53 participants were enrolled in this study.

Treatment Phase
Participant flow — Treatment Phase
MilestoneAll Participants
Started53
Completed43
Not completed10
Withdrew: Adverse event1
Withdrew: Death6
Withdrew: Withdrawal by subject2
Withdrew: Other1
Follow-Up Phase
Participant flow — Follow-Up Phase
MilestoneAll Participants
Started53
Completed44
Not completed9
Withdrew: Adverse event1
Withdrew: Death6
Withdrew: Withdrawal by subject1
Withdrew: Other1

Outcome measures

PrimaryNumber of Participants With All-Causality Treatment-Emergent Adverse Events (TEAEs)

An adverse event (AE) was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. All AEs that started after the first dosing but before the last dose plus the lag time (28 days) were TEAEs. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience; persistent disability/incapacity; congenital anomaly/birth defect. A severe TEAE was an event that prevented normal everyday activities. Severe TEAEs were assessed by the investigator.

Time frame:
From first dose of study intervention on Day 1 (baseline) up to 28 days post the last dose of study intervention (up to a maximum of 393 days)
Reported as:
Count of participants · Participants
Number of Participants With All-Causality Treatment-Emergent Adverse Events (TEAEs)
ParticipantsAll Participants
TEAEs45
Treatment-Emergent SAEs21
Severe TEAEs17
TEAEs Leading to Death6
Discontinuations From Study Due to TEAEs1
Permanent Discontinuations From Study Intervention Due to TEAEs1
Dosing Interruptions of the Study Intervention due to TEAEs3
PrimaryNumber of Participants With Treatment-Related TEAEs

An AE was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. All AEs that started after the first dosing but before the last dose plus the lag time (28 days) were TEAEs. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience; persistent disability/incapacity; congenital anomaly/birth defect. A severe TEAE was an event that prevented normal everyday activities. Severe TEAEs and treatment-related TEAEs were assessed by the investigator.

Time frame:
From first dose of study intervention on Day 1 (baseline) up to 28 days post the last dose of study intervention (up to a maximum of 393 days)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Related TEAEs
ParticipantsAll Participants
TEAEs3
Treatment-Emergent SAEs0
Severe TEAEs0
TEAEs Leading to Death0
Discontinuations From Study Due to TEAEs0
Permanent Discontinuations From Study Intervention Due to TEAEs0
Dosing Interruptions of the Study Intervention due to TEAEs1
SecondaryChange From Baseline (CFB) for Distance Walked During 6 Minute Walk Test (6MWT) at Months 6 and 12

As a measure of functional capacity, the 6MWT measured the distance a participant could walk on a straight course in 6 minutes. 6MWT was conducted in accordance with guidelines established by the American Thoracic Society at Month 6 and Month 12 visits. Baseline was defined as the last measurement prior to first dose of study intervention.

Time frame:
Baseline, months 6 and 12
Reported as:
Mean · Meters
Change From Baseline (CFB) for Distance Walked During 6 Minute Walk Test (6MWT) at Months 6 and 12
MetersAll Participants
Month 6-19.3 ± 73.36
Month 121.5 ± 91.29
SecondaryChange From Baseline for N Terminal Prohormone B Type Natriuretic Peptide (NT-proBNP) at Months 6 and 12

Plasma NT-proBNP is a guideline-mandated biomarker in heart failure. Baseline was defined as the last measurement prior to the first dose of study treatment.

Time frame:
Baseline, months 6 and 12
Reported as:
Mean · Nanograms per liter (ng/L)
Change From Baseline for N Terminal Prohormone B Type Natriuretic Peptide (NT-proBNP) at Months 6 and 12
Nanograms per liter (ng/L)All Participants
Month 6452.9 ± 2625.04
Month 12-422.2 ± 1581.82
SecondaryPercentage of Responders in Transthyretin (TTR) Stabilization Post Dose at Months 1, 6, and 12

Blood sample of approximate 10 mL was collected at baseline, Months 1, 6, and 12 visits for measurement of TTR and TTR tetramer concentrations. TTR concentration was obtained prior to urea denaturation and TTR tetramer concentration was obtained after urea denaturation. Month 1 visit occurred 1 month post Day 1 +/- 1 week, Month 6 visit occurred 6 months post Day 1 +/- 2 weeks, and Month 12 visit occurred 12 months post Day 1 +/- 2 weeks or within 2 weeks after end of treatment. Responder was the participant who achieved TTR stabilization (ie, who had been TTR stabilized). Declaring a participant to have been (TTR) 'stabilized' was defined as the participant whose percent stabilization was equal to or greater than 32%. Percent stabilization (%) was calculated as (\[fraction of initial {FOI} dosed - FOI baseline\] / FOI baseline)×100, and FOI was calculated as average TTR tetramer concentration (post-denaturation) / average TTR concentration (pre-denaturation).

Time frame:
Predose on Day 1 (baseline), predose and 3 hours post dose at Month 1 visit, 7 hours post dose at Month 6 visit, and 1 hour post dose at Month 12 visit
Reported as:
Number · Percentages of participants
Percentage of Responders in Transthyretin (TTR) Stabilization Post Dose at Months 1, 6, and 12
Percentages of participantsAll Participants
Predose at Month 196.4 (81.7 to 99.9)
3 hours post dose at Month 196.4 (81.7 to 99.9)
7 hours post dose at Month 696.2 (80.4 to 99.9)
1 hour post dose at Month 1294.7 (74.0 to 99.9)
SecondaryTTR Concentration at Baseline, Months 1, 6, and 12

One K2EDTA blood sample of approximate 10 mL was collected on Day 1 (baseline), and at Months 1, 6, and 12 visits for measurement of TTR concentration. Month 1 visit occurred 1 month post Day 1 +/- 1 week, Month 6 visit occurred 6 months post Day 1 +/- 2 weeks, and Month 12 visit occurred 12 months post Day 1 +/- 2 weeks or within 2 weeks after end of treatment.

Time frame:
Predose on Day 1 (baseline), predose and 3 hours post dose at Month 1 visit, 7 hours post dose at Month 6 visit, and 1 hour post dose at Month 12 visit
Reported as:
Mean · Milligrams per deciliter (mg/dL)
TTR Concentration at Baseline, Months 1, 6, and 12
Milligrams per deciliter (mg/dL)All Participants
Predose on Day 1 (baseline)12.70 ± 5.670
Predose at Month 119.73 ± 7.019
3 hours post dose at Month 119.58 ± 6.547
7 hours post dose at Month 621.48 ± 7.717
1 hour post dose at Month 1221.79 ± 7.003
SecondaryChange From Baseline for Kansas City Cardiomyopathy Questionnaire Overall Summary (KCCQ-OS) Scores at Months 6 and 12

The KCCQ is a self-administered, 23-item questionnaire. KCCQ-OS scores are transformed to a 0 to 100 range, with lower scores denoting poorer quality of life.

Time frame:
Day 1 (baseline), Months 6, and 12
Reported as:
Mean · Score on a scale of 100
Change From Baseline for Kansas City Cardiomyopathy Questionnaire Overall Summary (KCCQ-OS) Scores at Months 6 and 12
Score on a scale of 100All Participants
Month 6-0.4 ± 18.97
Month 12-0.3 ± 19.89
SecondaryChange From Baseline for EuroQol 5 Dimensions 5 Levels (EQ-5D-5L) Index Values at Months 6 and 12

The EQ-5D-5L is a brief, self-administered generic health status instrument. The instrument consists of 2 parts. In the first part, respondents are asked to rate their current health state on 5 dimensions (mobility, self-care, usual activities, pain or discomfort, and anxiety or depression) with each dimension having 5 levels of function (no problems, slight problems, moderate problems, severe problems, and extreme problems). The second part is a participant's self-rating of current health state on a Visual Analog Scale (EQ-5D VAS) with endpoints labeled 'best imaginable health state' (score of 100) and 'worst imaginable health state' (score of 0). The index values were calculated using the scoring algorithm based on preferences solicited from the Chinese population with 0 representing death and 1 representing full health. Higher EQ-5D-5L index value indicated a better quality of life. Change from baseline for EQ-5D-5L index values are reported for this outcome measure.

Time frame:
Day 1 (baseline), Months 6, and 12
Reported as:
Mean · Index value on a scale of 0-1
Change From Baseline for EuroQol 5 Dimensions 5 Levels (EQ-5D-5L) Index Values at Months 6 and 12
Index value on a scale of 0-1All Participants
Month 60.0 ± 0.24
Month 120.0 ± 0.21
SecondaryChange From Baseline for EuroQol VAS at Months 6 and 12

The EQ-5D-5L (5 levels version) is a brief, self-administered generic health status instrument. The instrument consists of 2 parts. In the first part, respondents are asked to rate their current health state on 5 dimensions (mobility, self-care, usual activities, pain or discomfort, and anxiety or depression) with each dimension having 3 levels of function (no problems, slight problems, moderate problems, severe problems and extreme problems). The second part is a participant's self-rating of current health state on a EQ-5D VAS with endpoints labeled 'best imaginable health state' (score of 100) and 'worst imaginable health state' (score of 0). The scores from the 5 dimensions may be used to calculate a single index value, also known as a utility score. EQ-5D VAS scores are reported for this outcome measure.

Time frame:
Day 1 (baseline), Months 6, and 12
Reported as:
Mean · Score on a scale of 100
Change From Baseline for EuroQol VAS at Months 6 and 12
Score on a scale of 100All Participants
Month 6-0.6 ± 20.23
Month 123.4 ± 15.65
SecondaryChange From Baseline for Physical Component Summary (PCS) for Short-Form Survey 12 (SF-12) at Months 6 and 12

SF-12 is developed as a shorter alternative to the SF-36 for use in large-scale studies. It is an instrument with different weights for scoring physical and mental health, and measures health-related quality of life with 12 items categorized in eight areas: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. This questionnaire was completed by the participant after the KCCQ and EQ-5D-5L, and prior to other required visit assessments. PCS score ranges from 0 to 100, and higher PCS score indicates a better quality of life. Change from baseline for PCS for SF-12 is reported for this outcome measure.

Time frame:
Day 1 (baseline), Months 6, and 12
Reported as:
Mean · Score on a scale of 100
Change From Baseline for Physical Component Summary (PCS) for Short-Form Survey 12 (SF-12) at Months 6 and 12
Score on a scale of 100All Participants
Month 60.1 ± 8.24
Month 12-0.0 ± 9.14
SecondaryChange From Baseline for Mental Component Summary (MCS) for SF-12 at Months 6 and 12

SF-12 is developed as a shorter alternative to the SF-36 for use in large-scale studies. It is an instrument with different weights for scoring physical and mental health, and measures health-related quality of life with 12 items categorized in eight areas: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. This questionnaire was completed by the participant after the KCCQ and EQ-5D-5L, and prior to other required visit assessments. MCS score ranges from 0 to 100, and higher MCS score indicates a better quality of life. Change from baseline for MCS for SF-12 is reported for this outcome measure.

Time frame:
Day 1 (baseline), Months 6, and 12
Reported as:
Mean · Score on a scale of 100
Change From Baseline for Mental Component Summary (MCS) for SF-12 at Months 6 and 12
Score on a scale of 100All Participants
Month 61.4 ± 10.60
Month 121.5 ± 12.54
SecondaryPlasma Concentrations of Tafamidis at Months 1, 6, and 12

Blood samples of approximately 3 mL, to provide an approximately 1 mL plasma, were collected for measurement of plasma concentrations of tafamidis at Months 1, 6, and 12 visits. Month 1 visit occurred 1 month post Day 1 +/- 1 week, Month 6 visit occurred 6 months post Day 1 +/- 2 weeks, and Month 12 visit occurred 12 months post Day 1 +/- 2 weeks or within 2 weeks after end of treatment.

Time frame:
Predose and 3 hours post dose at Month 1 visit, 7 hours post dose at Month 6 visit, and 1 hour post at Month 12 visit
Reported as:
Mean · nanograms per milliliter (ng/mL)
Plasma Concentrations of Tafamidis at Months 1, 6, and 12
nanograms per milliliter (ng/mL)All Participants
Predose at Month 110410 ± 5521.1
3 hours post dose at Month 112040 ± 4950.1
7 hours post dose at Month 614100 ± 5950.5
1 hour post dose at Month 1211950 ± 5475.8

Adverse events

Collected over From the first dose of study intervention up to 28 days post the last dose of study intervention (up to a maximum of 393 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
All Participants6/53 (11.3%)21/53 (39.6%)35/53 (66%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventAll Participants
Cardiac failureCardiac disorders6/53
Cardiac failure acuteCardiac disorders3/53
COVID-19Infections and infestations3/53
Disease progressionGeneral disorders2/53
PneumoniaInfections and infestations2/53
Atrial thrombosisCardiac disorders1/53
Cardiorenal syndromeCardiac disorders1/53
Hereditary neuropathic amyloidosisCongenital, familial and genetic disorders1/53
VomitingGastrointestinal disorders1/53
Oedema peripheralGeneral disorders1/53
Most frequent other events
Most frequent other events
EventAll Participants
COVID-19Infections and infestations12/53
DiarrhoeaGastrointestinal disorders6/53
HyperuricaemiaMetabolism and nutrition disorders5/53
VomitingGastrointestinal disorders4/53
Hepatic function abnormalHepatobiliary disorders4/53
NasopharyngitisInfections and infestations4/53
PneumoniaInfections and infestations3/53
HaematuriaRenal and urinary disorders3/53
CoughRespiratory, thoracic and mediastinal disorders3/53

Baseline characteristics

Safety analysis set included all enrolled participants who took at least 1 dose of tafamidis free acid 61 mg soft capsule.

Age, Categorical
Age, Categorical(Participants)All Participants
<=18 years0
Between 18 and 65 years36
>=65 years17
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female6
Male47
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)All Participants
Asian53
08

Study locations

9 sites
  • Peking University First Hospital
    Beijing, Beijing 100034, China
  • Peking University Third Hospital
    Beijing, Beijing 100191, China
  • Peking Union Medical College Hospital
    Beijing, Beijing 100730, China
  • Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology
    Wuhan, Hubei 430030, China
  • The Second Xiangya Hospital of Central South University
    Changsha, Hunan 410011, China
  • The First Affiliated Hospital of Dalian Medical University
    Dalian, Liaoning 116014, China
  • West China Hospital of Sichuan University
    Chengdu, Sichuan 610041, China
  • The Second Affiliated Hospital of Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310009, China
  • Ruijin Hospital, Shanghai Jiaotong University School of Medicine
    Shanghai, 200025, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2021 to primary completion in Oct 2023, 26 months.

Results were first posted in Dec 2024, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2021
First posted
Mar 24, 2021
StartActual
Jul 22, 2021
Primary completionActual
Oct 16, 2023
CompletionActual
Oct 16, 2023
Results first posted
Dec 18, 2024
Last update
Dec 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04814186
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Mar 24, 2021
Start date
Jul 22, 2021
Primary completion
Oct 16, 2023
Completion
Oct 16, 2023
Results posted
Dec 18, 2024
Last update
Dec 18, 2024

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tafamidis

Start the discussion